Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27269741

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jul
First author
Antonia SJ

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):846-847. doi: 10.1016/S1470-2045(16)30159-0.
    note
    Source null
    related pmid
    27269739
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Jul;17(7):e270. doi: 10.1016/S1470-2045(16)30221-2.
    note
    Source null
    related pmid
    27733294
    relationship
    Erratum in
  3. citation
    Ann Transl Med. 2016 Oct;4(Suppl 1):S5. doi: 10.21037/atm.2016.09.35.
    note
    Source null
    related pmid
    27867973
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2019 Feb;20(2):e70. doi: 10.1016/S1470-2045(19)30018-X.
    note
    Source null
    related pmid
    30712803
    relationship
    Erratum in

Authors and identifiers

  1. name
    Antonia SJ
    type
    Author
  2. name
    López-Martin JA
    type
    Author
  3. name
    Bendell J
    type
    Author
  4. name
    Ott PA
    type
    Author
  5. name
    Taylor M
    type
    Author
  6. name
    Eder JP
    type
    Author
  7. name
    Jäger D
    type
    Author
  8. name
    Pietanza MC
    type
    Author
  9. name
    Le DT
    type
    Author
  10. name
    de Braud F
    type
    Author
  11. name
    Morse MA
    type
    Author
  12. name
    Ascierto PA
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Antonia SJ
    type
    Author
  2. name
    López-Martin JA
    type
    Author
  3. name
    Bendell J
    type
    Author
  4. name
    Ott PA
    type
    Author
  5. name
    Taylor M
    type
    Author
  6. name
    Eder JP
    type
    Author
  7. name
    Jäger D
    type
    Author
  8. name
    Pietanza MC
    type
    Author
  9. name
    Le DT
    type
    Author
  10. name
    de Braud F
    type
    Author
  11. name
    Morse MA
    type
    Author
  12. name
    Ascierto PA
    type
    Author
bibliography ids
  1. nci-bib-78b237ae4b3f523fb6f72063
book metadata
content sha256
01ecb1bcbb6285b6b19e2482e8fc432ef68f45ca470a41131288caa3535960be
document type
citation
dois
  1. 10.1016/S1470-2045(16)30098-5
electronic publication date
display
2016 Jun 4
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27269741
immutable id
pubmed:27269741@01ecb1bcbb6285b6b19e2482e8fc432ef68f45ca470a41131288caa3535960be
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
883-895
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):846-847. doi: 10.1016/S1470-2045(16)30159-0.
    note
    Source null
    related pmid
    27269739
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Jul;17(7):e270. doi: 10.1016/S1470-2045(16)30221-2.
    note
    Source null
    related pmid
    27733294
    relationship
    Erratum in
  3. citation
    Ann Transl Med. 2016 Oct;4(Suppl 1):S5. doi: 10.21037/atm.2016.09.35.
    note
    Source null
    related pmid
    27867973
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2019 Feb;20(2):e70. doi: 10.1016/S1470-2045(19)30018-X.
    note
    Source null
    related pmid
    30712803
    relationship
    Erratum in
outcomes validated
false
pmid
27269741
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
3f19b8fe972423cac137ebe4a9a8f2f55611c332f41918fabf9136171660dcf4
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jul
precision
month
year
2016
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Comparative Study
  4. Journal Article
  5. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27269741/
title
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Preserved source evidence · Not medical advice